Adicet Bio, Inc. — Director's Dealing 2018

Jan 26, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: resTORbio, Inc. (TORC)
CIK: 0001720580
Period of Report: 2018-01-25

Reporting Person: SILVERSTEIN JONATHAN (Director, 10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (2425485)		Indirect
Series B Preferred Stock	$		Common Stock (1871569)		Indirect

Footnotes

F1: All series of Convertible Preferred Stock will automatically convert into resTORbio, Inc. common stock on a 1.2804-for-1 basis immediately prior to the closing of the initial public offering and have no expiration date.

F2: The shares of Series A Preferred Stock and Series B Preferred Stock are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a member of Advisors.

F3: Each of GP VI, Advisors, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.